A randomized ERCP study in older adults reported slower induction but shorter recovery measures with remimazolam than with propofol. Both groups received opioids, so the comparison concerns two sedation regimens rather than isolated hypnotic exposure.
The paper describes 140 older patients, allocated equally between remimazolam-plus-opioid and propofol-plus-opioid groups. Remimazolam had a longer induction time and a lower first-induction success rate, while eye-opening, recovery of consciousness, and recovery-room residence were shorter. The investigators also reported fewer composite adverse reactions in that group: 18.57% versus 31.43%.
A sedative can take longer to reach an induction endpoint yet be associated with a shorter recovery interval under the studied protocol. Combining those results into a single label such as faster anesthesia would conceal the tradeoff. Similarly, a composite adverse-event difference does not establish that every individual adverse event was reduced.
The authors identify a single-center study and limited generalizability beyond the enrolled older-adult population. Opioid co-administration, dosing, procedural stimulation, and recovery criteria remain part of the intervention. These results cannot establish a universal offset time or show that an individual patient had recovered memory or judgment at eye-opening. A case review should preserve the separate timestamps and define what each observed recovery milestone actually measured.
This original analysis uses the supplied paper: Comparative analysis of the therapeutic efficacy of remimazolam tosylate and propofol in older adult. The interpretation above separates the authors’ findings from their implications for evidence review.
Explore related material through this site’s benzodiazepine articles and remimazolam research discussions.